Offering proceeds to be used to integrate the Tissue of Origin test
By Devika Patel
Knoxville, Tenn., Sept. 20 - Response Genetics, Inc. said it has arranged a $1.91 million registered direct offering of stock. Ladenburg Thalmann & Co. Inc. is the agent.
The company will sell 932,805 common shares at $2.05 apiece. The price per share is identical to the Sept. 19 closing share price.
Settlement is expected Sept. 25.
Proceeds will be used to expedite the integration of the recently acquired Tissue of Origin test for difficult-to-diagnose solid tumors and all associated assets.
Response Genetics is a Los Angeles company that researches and develops clinical diagnostic tests for cancer.
| Issuer: | Response Genetics, Inc.
|
| Issue: | Common shares
|
| Amount: | $1,912,250
|
| Shares: | 932,805
|
| Price: | $2.05
|
| Warrants: | No
|
| Agent: | Ladenburg Thalmann & Co. Inc.
|
| Pricing date: | Sept. 20
|
| Settlement date: | Sept. 25
|
| Stock symbol: | Nasdaq: RGDX
|
| Stock price: | $2.05 at close Sept. 19
|
| Market capitalization: | $72.19 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
